World-class finished dosage manufacturing facility in Pharma SEZ with USFDA-approved OSD and Injectable lines for potent and oncology products
Shilpa Medicare Ltd. - Unit IV (Jadcherla) is our world-class finished dosage manufacturing facility strategically located in the Telangana State Industrial Infrastructure Corporation (TSIIC) Pharma Special Economic Zone (SEZ), designed for contract manufacturing and dosage development of potent products including oncology formulations.
Located in a Special Economic Zone, this facility offers strategic advantages for both domestic and international contract manufacturing, with state-of-the-art infrastructure for oral solid dosage forms and injectable products.
Total land area of 14 acres with 6 acres constructed and 8 acres reserved for future expansion and scalability
Comprehensive capabilities in both Oral Solid Dosage (OSD) and Injectable manufacturing with dedicated blocks
Specialized infrastructure for manufacturing potent products including oncology formulations with advanced containment
USFDA, EU GMP, ANVISA, COFEPRIS, and DIGEMID approved facility serving multiple regulatory markets
The facility is strategically designed for contract manufacturing and dosage development of potent products, offering comprehensive CDMO services from formulation development through commercial-scale production.
End-to-end formulation development services for oral solids and injectables with regulatory support
Seamless scale-up from development batches to commercial production with validated processes
Specialized handling and manufacturing of high-potency and oncology formulations with containment
Regulatory Authority / Agency | Status | Approved Scope |
|---|---|---|
| USFDA (United States) | ✅ APPROVED | OSD & Injectable |
| EU GMP (European Union) | ✅ APPROVED | OSD & Injectable |
| ANVISA (Brazil) | ✅ APPROVED | Injectable |
| COFEPRIS (Mexico) | ✅ APPROVED | Injectable |
| DIGEMID (Peru) | ✅ APPROVED | Injectable |
Located in the Telangana State Industrial Infrastructure Corporation (TSIIC) Pharma Special Economic Zone, this facility enjoys strategic advantages:
The Jadcherla facility is strategically located in the TSIIC Pharma Special Economic Zone, providing excellent connectivity to major transportation hubs:
With 8 acres of land available for future expansion, the facility is designed to scale operations and add new manufacturing capabilities as per client requirements and market demands.
